Search

ObjectiveTo understand the impact of vaccine hesitancy on coronavirus disease 2019 (COVID-19) vaccination status among the elderly population in Beijing, and to provide policy recommendations for the implementation of the national strategy to promote COVID-19 vaccination among the elderly. MethodsA stratified random sampling method was used to recruit 800 residents aged ≥ 60 years for a face-to-face survey in October 2020. A self-designed questionnaire was used to collect relevant information, and the 5C scale was used to capture relevant predictors of vaccination behavior among participants. Unconditional multivariate logistic regression models were used to analyze the effect of vaccine hesitancy on COVID-19 vaccination. ResultsOf the 720 eligible participants included in the analysis, 541 (75.14%) had received the first dose of COVID-19 vaccine. Participants′ total score on the 5C scale was 4.84 ± 1.06 after positive and negative conversion, with dimensional scores of 8.94 ± 1.39 for confidence, 1.92 ± 2.26 for complacency, 1.46 ± 1.94 for constraints, 7.44 ± 2.63 for calculation, and 8.10 ± 1.68 for collective responsibility. The numbers (percentages) of participants classified as having high, moderate, and low vaccine hesitancy were 240 (33.33%), 232 (32.22%), and 248 (34.44%), respectively. After adjustment for sex, age, education, marital status, monthly household income per capita, smoking, alcohol consumption, social activities in the previous month, and chronic disease, the results of multivariable logistic regression indicated that participants with a higher collective responsibility score were more likely to have a higher COVID-19 vaccination rate (odds ratio [OR] = 1.21, 95% confidence interval [CI]: 1.00 – 1.46). In contrast, higher levels of complacency (OR = 0.76, 95%CI: 0.64 – 0.92), constraints (OR = 0.83, 95%CI: 0.69 – 0.99), and calculation (OR = 0.72, 95%CI: 0.58 – 0.89) were associated with lower vaccination rates. Participants with moderate and low vaccine hesitancy were more likely to be vaccinated, with an OR (95%CI) of 2.19 (1.44 – 3.33) and 4.03 (2.51 – 6.45), respectively. ConclusionThe COVID-19 vaccination rate among the elderly in Beijing is relatively low, with higher vaccination rates observed among those with lower levels of vaccine hesitancy.

The global pandemic of the coronavirus disease 2019 (COVID-19) has had a serious impact on global life safety and economic development. Vaccination with the coronavirus disease vaccine (COVID-19 vaccine) is an important measure to prevent infection, reduce the incidence and severity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Currently, there are six different technological routes for COVID-19 vaccines worldwide, including protein subunit vaccines, nucleic acid vaccines (mRNA vaccines and DNA vaccines), viral vector vaccines, inactivated vaccines, virus-like particle vaccines, and attenuated vaccines. Sequential immunization strategy is a valid approach for solving vaccine shortages, responding to viral variants, and improving vaccine efficacy by administering COVID-19 vaccines of different technological routes at specific time intervals and doses. Many scholars at home and abroad have conducted research on the sequential immunization strategy of COVID-19 vaccines. This article provided an overview of the research on the sequential immunization strategy of COVID-19 vaccines at home and abroad in five aspects: COVID-19 inactivated vaccine and mRNA vaccine, COVID-19 inactivated vaccine and adenovirus vector vaccine, COVID-19 inactivated vaccine and protein subunit vaccine, COVID-19 adenovirus vector vaccine and mRNA vaccine, COVID-19 adenovirus vector vaccine and protein subunit vaccine, aiming to provide reference for the inoculation and formulation of immunization strategies for COVID-19 vaccines.

Objective To investigate the vaccination status and vaccination willingness of novel coronavirus in HIV/AIDS population in Yunnan. Methods From October 2021 to June 2022, a questionnaire survey was conducted among 2 180 HIV/AIDS patients in Kunming, Qujing, Yuxi, Zhaotong, Puer, Baoshan, Lincang, Honghe, Wenshan, Xishuangbanna, Dali, Dehong and Nujiang prefectures. The questionnaire included age, sex, education, nationality, education level, vaccination, adverse reactions within 7 days after the vaccination, safety of COVID-19 vaccine, awareness of effectiveness, vaccination willingness and so on. Results Among the subjects, 2 109 completed 3 injections, accounting for 96.74%, and 71 were not vaccinated, accounting for 3.26%. Within 7 days of inoculation, local adverse reactions occurred in 116 cases, accounting for 5.50%, and systemic adverse reactions occurred in 56 cases, accounting for 2.66%. Injection site pain, fatigue and muscle pain accounted for the highest proportion of adverse symptoms in different sex, age and the Han nationality, while the proportion of minority adverse reactions was very low, and there was no difference among the different sex and age (P > 0.05). The main reasons for the reluctance of HIV/AIDS population to be vaccinated were (recommended by doctors) that HIV/AIDS patients could not be vaccinated (67.61%) and may have serious adverse reactions after the vaccination (19.72%). The factors affecting the vaccination were found by logistic regression analysis, whether they were worried about infecting novel coronavirus (OR = 0.121, 95%CI = 0.083～0.640, P < 0.001) and how much they knew about COVID-19 vaccine ( OR = 28.932, 95%CI = 15.469 ～54.115, P < 0.001), safety of vaccination (OR = 13.953, 95%CI = 4.819 ～40.404, P < 0.001) and belief in the preventive effect of vaccine (OR = 14.017, 95%CI = 4.752～41.348, P < 0.001) were significant factors affecting vaccination. Among the 13 prefectures and cities, Dehong (20), Zhaotong (21) and Lincang (14) had the largest number of unvaccinated people. Conclusion After the mass vaccination, the rate of adverse reaction in HIV/AIDS population is low, the symptoms are mild, the correct and scientific advice and guidance from doctors and the full understanding of the harmfulness of the disease, the safety, prevention and effectiveness of the vaccine are the key to complete vaccination and put an end to vaccine hesitancy. [ABSTRACT FROM AUTHOR]

ObjectiveCOVID-19 vaccination is critical for pandemic control， especially in the elderly. Compared with developed countries， the rate of full vaccination and booster vaccination for the elderly in China is low， making it urgent to accelerate the process of vaccination for the elderly in China.MethodsThis study summarizes the policy experiences of the United Kingdom， the United States， Singapore， and South Korea by sorting relevant literature and government websites， analyzes the current performance and reasons for COVID-19 vaccination among the elderly in China， and explores strategic suggestions for improving COVID-19 vaccination in the elderly in terms of vaccination priority groups， service provision， and vaccination intention.ResultsIt is important to vaccination rate for the elderly in China by focusing on the priority vaccination population， establishing a permanent mechanism based on the family doctor system， and increasing the willingness to vaccinate.ConclusionContinued reinforcement of COVID-19 vaccination for the elderly is needed， and the existing vaccination model is overwhelming. We should establish a permanent mechanism based on the family doctor system to transfer from a mobilization model to a regular vaccination model.

Objective To investigate the factors influencing the hesitation of occupational pneumoconiosis patients in Guangdong Province to receive COVID-19 vaccine so as to provide reference for eliminating their "vaccine hesitancy". Methods From September 2022 to November 2022, a cohort of patients aged 18 years and above were selected from Guangdong occupational pneumoconiosis report system as the subjects in the survey by systematic sampling method. Questionnaire survey was conducted by telephone follow-up, and the acquired data were analyzed by multiple stepwise regression. Results A total of 339 questionnaires meeting the requirements were obtained, including 14 items affecting factors of "vaccine hesitation". According to the standard partial regression coefficient, nine factors were correlated with vaccine hesitancy, in the order from the largest to the smallest correlation, e.g., "I would be more willing to get vaccinated if recommended by doctors, community and other professionals, " "I believe that vaccines approved by the state are safe, " and "If the government recommends vaccination, I believe it will be beneficial.", etc. Conclusion The government should carry out psychological interventions for coping strategies and health education measures to provide objective information about existing and developing vaccines and meanwhile pay more attention to the vaccine hesitancy of occupational disease patients so so to increase the vaccination rate and eliminate their vaccine hesitancy for the ultimate purpose of giving full play to the important protective role of the novel coronavirus vaccine in preventing Covid-19. [ABSTRACT FROM AUTHOR]

Anaphylactic shock is a serious and rare adverse reaction， which can be life-threatening if not treated in time. COVID-19 vaccine is a newly marketed vaccine， and people pay high attention to its adverse reactions. This report summarized the investigation and management process of a case of anaphylactic shock after inoculation with COVID-19 vaccine， in order to provide reference for standardizing the diagnosis and management of anaphylactic shock after vaccination.

ObjectiveTo investigate the specific anti-SARS-CoV-2 antibody in adults and above after initial vaccination with inactivated COVID-19 vaccine， and determine the influencing factors.MethodsIn this study， residents aged 18 and above who had completed two doses of inactivated COVID-19 vaccine in Deqing County， Huzhou City， Zhejiang Province were included. Information such as gender， age， type of vaccine and vaccination time were collected， and serum specimens were sampled. Anti-SARS-CoV-2 receptor binding domain （RBD） antibody was quantitatively examined by enzyma-linked immunosorbent assay （ELISA） and influencing factors were determined.ResultsThe median concentration of anti-SARS-CoV-2 IgG antibody in the residents vaccinated with an inactivated booster vaccine was higher than that in those vaccinated with only two doses of COVID-19 vaccine or single dose （P

ObjectiveTo examine the incidence of adverse events following immunization (AEFI) among old people receiving booster dose of coronavirus disease 2019 (COVID-19) vaccine and to provide reference data for evaluating the safety of COVID-19 vaccine booster immunization in the population. MethodsUsing a self-designed questionnaire on AEFI, we conducted person-to-person telephone interviews among 1 157 vaccinees aged 60 years and above 7 – 14 days after receiving booster dose of COVID-19 vaccine at a community healthcare service station between October 2021 and March 2022. ResultsOf all the elderly interviewed, 122 (10.54%) reported AEFI. Local reaction was the most frequently reported AEFI (112 person times in 90 participants) and the majority (64.29%, 72/112 person times) of the local reactions was pain at the injection site. Of the 90 participants reporting AEFI, 58.89% (n = 53) had their adverse events spontaneously improved one or two days after the vaccination. Totally 46 person times of systemic reactions were reported by 38 participants, and 32.61% (15 person times) of the systemic reactions was fatigue; the reported systemic reactions also spontaneously improved in 21 (55.26%) of the sufferers one or two days after the vaccination. There were 6 participants reporting both local and systemic reaction. No significant association of hypertension, diabetes and hyperlipidemia with the occurrence of AEFI was observed. There was a significant difference in the incidence of AEFI among the participants having different booster immunization schedules (χ2 = 14.705，P < 0.05). Among the participants having inactivated vaccines, the incidence of AEFI was 12.59% (36/286) for those with the booster dose of homologous vaccine from the same manufacture as their routine vaccination and the incidence was 9.50% (67/705) for those with the booster dose of homologous vaccine but from different manufacture; among the participants having two doses recombinant novel coronavirus vaccine (type 5 adenovirus vector, abbreviated as adenovirus) the AEFI incidence was 13.33% (2/15); among the participants having non homologous vaccine booster dose, the AEFI incidence was 22.41% (13/58) or 4.30% (4/93) for those with the booster dose of adenovirus vaccine or recombinant novel coronavirus vaccine (CHO cell vaccine). ConclusionThe incidence of AEFI was lower in the elderly after receiving booster dose of COVID-19 vaccine with different immunization schedules and most of the AEFI were transient, self-limiting reactions, indicating a good safety of booster immunization of COVID-19 vaccine .

ObjectiveTo construct a decision-making process model on vaccination of coronavirus disease 2019 (COVID-19) vaccine and to explore reasons of unwilling to have the vaccination from public perspective for providing theoretical evidences to COVID-19 vaccination promotion. MethodsUsing a self-designed open-ended questionnaire on COVID-19 vaccine hesitancy, we conducted a survey among 347 students in a medical university during March 27 – 29, 2021 – one week after the students′ applying voluntarily for COVID-19 vaccination. Word frequency and text node analysis on collected information were carried out and word cloud maps were generated with NVivo 12 software. A theoretical framework for vaccination decision-making process model was constructed based on grounded theory. ResultsValid information were collected from all the participants. In the respondents′ responses in writing about reasons for having COVID-19 vaccination, the words with high frequency included COVID-19, prevention, vaccination, and free of charge; while, safety, vaccine, effectiveness and adverse reaction were among the high frequency words in the writings on COVID-19 vaccine hesitancy. In the respondents′ writing texts, 3 parent nodes and 9 child nodes were identified. According to theoretical models of bio-psycho-social medicine, protective behavior decision, and vaccine hesitation/vaccination willingness and considering the results of previous studies, the public motivation for COVID-19 vaccination could be summarized into three aspects with nine causal factors as following: objective biological determination (factors relevant to virology/pharmacology and physiology/pathology), subjective psychological determination (personal risk and benefit judgment, vaccine safety, vaccine efficacy, and perceived social responsibility), and social determination (service accessibility, information accessibility). The three determinant aspects with nine relevant factors ought to be concerned in the construction of theoretical framework of vaccination decision-making process model for the public. ConclusionA vaccination decision-making process model for the public was preliminarily constructed for the promotion of COVID-19 vaccination willingness and behavior in Chinese population.

ObjectiveTo compare measures and effectiveness of case detection, transmission control, and vaccination for containment of coronavirus disease 2019 (COVID-19) epidemic in Australia, South Korea, Singapore, Israel, and India for providing evidences to the development of strategies on worldwide prevention and control of the epidemic. MethodsThe data on COVID-19 epidemic from January 1st 2020 through 2021 in the five countries were retrieved from the website of Our World in Data. Country-specific effects of non-pharmacological interventions (NPIs) and vaccinations on infectious source tracing, intercepting transmission, and protecting susceptible populations in the five countries were assessed by comparing correlations between the daily numbers of testing and incidence cases, the Oxford-stringency index and daily incidences, and the number of fully vaccinated persons per 100 population and daily mortalities. ResultsThe severity of COVID-19 epidemic was controlled by increased daily number of detection in a certain extent and the daily number of confirmed incidence cases decreased after the day with the highest detection number. The Oxford-stringency index increased with the worsening of COVID-19 epidemic but decreased somewhat with the weakening of the epidemic and the decrease in the index could relate to a rebound of the epidemic. The case-fatality rate of COVID-19 decreased with the increase of fully vaccination rate. ConclusionCountries around the world should actively learn from international experience, follow the laws of epidemiology, start from controlling the source of infection, cutting off the transmission route and protecting susceptible people, adapt NPIs and promote booster vaccination universally, further research and development, for coping effectively with the global public health challenge.

SARS-CoV-2 is responsible for the novel coronavirus infection pandemic, and vaccination is an effective precaution against it. However, due to vaccine hesitancy, certain groups of people, especially those with chronic diseases and immune disorders, are on the fence about novel coronavirus vaccination. Atopic dermatitis (AD) is a chronic inflammatory skin disease associated with immune disorders, and there are no clear guidelines on whether patients with AD should be vaccinated with the COVID-19 vaccine. In this paper, the intersection of COVID-19 vaccine on AD patients’ symptoms will be sorted out, and the issue of whether AD patients should be vaccinated with COVID-19 vaccine will be discussed in combination with the relevant recommendations on AD patients’ vaccination at home and abroad, as well as the retrospective investigation of AD patients’ vaccination with COVID-19 vaccine, to provide a reference for medical staff and relevant researchers. [ABSTRACT FROM AUTHOR]

The new coronavirus is still in the global pandemic stage. At present, the Delta strain and the Omicron strain are the main circulating strains. The mutant strain has stronger infectivity than the original virus. In the content of COVID-19 pandemic, social public resources and medical resources may be affected, which lead to the medical treatment being delayed or interrupted in some patients with malignant tumors. Based on relevant research and clinical practice at home and abroad, the Cancer Support Therapy Committee of China Anti-Cancer Association and the Cancer Clinical Chemotherapy Committee of China Anti- Cancer Association, in the light of China's national conditions and the availability of resources such as vaccines and antiviral drug, to formulate a consensus of Chinese experts on issues related to the prevention, treatment and management of patients with solid tumors. The main contents include the vaccination of cancer patients with COVID-19, the optimization of medical resources, and the timing of restarting anti-tumor therapy after COVID-19 infection. This article is aimed at providing reference for clinical practice. [ABSTRACT FROM AUTHOR]

Copyright of Angle Health Law Review is the property of Angle Publishing Co., Ltd. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Objective To analyze IgG test results of serum SARS-CoV-2 antibody in people after booster vaccinations against SARS-CoV-2, and to provide a basis for the booster vaccination. Methods There were 314 healthy individuals who had been vaccinated with the COVID-19 vaccine. Depending on their inoculation situation, they were divided into three groups: the booster injection group (1 week to 2 months after booster vaccination)of 205 cases, <180 days after two doses group (<180 days after two doses of COVID-19 vaccine)of 49 cases, and >180 days after two doses group (>180 days after two doses of COVID-19 vaccine)of 60 cases. The positive rate of IgG in serum of the three groups was measured using the colloidal gold method. Results The serum COVID-19 antibody IgG positive rates were 83. 9% in the booster injection group, 18. 4% in the <180 days after two doses group, and 5. 0% in the >180 days after two doses group, with statistically significant difference between any two groups (all P<0. 05). In the booster injection group, the serum COVID-19 antibody IgG positive rate was 85. 2% in people who received a booster injection more than a month, while those who received a booster injection less than a month had a positive rate of 75. 9%, and there was no significant difference between these two groups (P>0. 05). In the booster injection group, the positive rates of serum COVID-19 antibody IgG were 85. 1% in males and 82. 4% in females, with no significant difference (P>0. 05). In the booster injection group, people at the age of 18 and 50 had a positive serum COVID-19 antibody IgG rate of 86. 0%, while those over 50 had a positive rate of 58. 3%, and there was significant difference between them (P<0. 05). Conclusions Compared with two injections of the COVID-19 vaccine, the booster injection can significantly increase the positive rate of the antibody IgG of COVID-19, which results in a stronger immune response. There is a lower IgG positive rate of COVID-19 antibodies in those aged over 50 years following the booster dose of COVID-19 vaccine than in those aged 18- 50 years. [ABSTRACT FROM AUTHOR]

】根据国务院应对新型冠状病毒肺炎疫情联防联控工作机制和上海市人民政府有关部署，上海市从2020年 10月份起压茬推进、稳妥有序对2 000余万在沪各类人群开展了新型冠状病毒疫苗接种，截至2021年底接种累计 超5 000万剂次，2021年疫苗接种量较2020年增加5倍。回顾2020-2021年上海市新型冠状病毒疫苗群体性接种 工作，对接种方案设计、组织实施、工作成效等方面进行总结和分析，并提出下一步工作的重点和方向性建议。. [ABSTRACT FROM AUTHOR]

In the ongoing COVID-19 pandemic, systemic lupus erythematosus, due to immune abnormalities caused by autoimmune diseases and low immune function due to immunosuppressant therapy, patients with systemic lupus erythematosus( SLE) have a higher susceptibility to SARS-COV-2. Meanwhile, infection is an important risk factor for death in patients with SLE, and can also lead to active and worsening of patients with SLE, and resulting in a worse prognosis. However, there are insufficient clinical data on COVID-19 vaccine in patients with SLE, so that COVID-19 vaccine in patients have certain controversies. Based on three types of vaccines widely inoculated in China and the basic situation of SLE, this paper proposes recommendations of COVID-19 vaccine for SLE patients by combing the international recommendations on COVID-19 vaccine for reference of medical professionals. [ABSTRACT FROM AUTHOR]

Copyright of China Tropical Medicine is the property of China Tropical Medicine Editorial Office and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Strengthening strategic science and technology forces is the key to achieve scientific and technological self-reliance and self-improvement. China’s COVID-19 vaccine research and development has achieved a stage success and such success has inseparable relationship with the national strategic science and technology forces. This paper starts from the current situation of COVID-19 vaccine R&D in China and in the world, further considers and explores the mission positioning, top-level design, and strengthening methods of China’s strategic science and technology forces, and proposes corresponding policy suggestions on strengthening China’s strategic science and technology force, through analyzing the successful experience of China’s COVID-19 vaccine R&D. [ABSTRACT FROM AUTHOR]

The new coronavirus is still in the global pandemic stage. At present, the Delta strain and the Omicron strain are the main circulating strains. The mutant strain has stronger infectivity than the original virus. In the content of COVID-19 pandemic, social public resources and medical resources may be affected, which lead to the medical treatment being delayed or interrupted in some patients with malignant tumors. Based on relevant research and clinical practice at home and abroad, the Cancer Support Therapy Committee of China Anti-Cancer Association and the Cancer Clinical Chemotherapy Committee of China Anti-Cancer Association, in the light of China's national conditions and the availability of resources such as vaccines and antiviral drug, to formulate a consensus of Chinese experts on issues related to the prevention, treatment and management of patients with solid tumors. The main contents include the vaccination of cancer patients with COVID-19, the optimization of medical resources, and the timing of restarting anti-tumor therapy after COVID-19 infection. This article is aimed at providing reference for clinical practice.